Evidence map›Paper›PMID 40123633›Full record

ArticleIndian journal of clinical biochemistry : IJCB2025

Phenotypic Evolution in Fabry Disease: Our Experience in Indian Cohort.

Usha Dave, Srilatha Kadali, Tajamul Hussain, Ananthaneni Radhika, Sagar Patel, Nirav Patel, Shaik Mohammad Naushad

Abstract read
In one paragraph

Article in Indian journal of clinical biochemistry : IJCB, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Usha DaveNavigene Genetic Science Laboratory, MILS International India, Mumbai, India.
Srilatha KadaliDepartment of Biochemical and Molecular Genetics, Yoda Diagnostics Pvt. Ltd, Hyderabad, 500016 Telangana India.
Tajamul HussainResearch Chair for Biomedical Applications of Nanomaterials, Biochemistry Department, College of Science, King Saud University, 11451 Riyadh, Saudi Arabia.
Ananthaneni RadhikaDepartment of Biochemical and Molecular Genetics, Yoda Diagnostics Pvt. Ltd, Hyderabad, 500016 Telangana India.
Sagar PatelOrange Children Hospital, Ahmedabad, India.
Nirav PatelOrange Children Hospital, Ahmedabad, India.
Shaik Mohammad NaushadDepartment of Biochemical and Molecular Genetics, Yoda Diagnostics Pvt. Ltd, Hyderabad, 500016 Telangana India.ORCID 0000-0001-8952-9581

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current study aimed to explore phenotypic evolution in Fabry disease according to demographics, genotype, specific enzyme activity and pathogenicity scores. We integrated clinical, biochemical, and genomic data of 88 Fabry cases (23 from our cohort, 65 from other published data on Indians) to achieve this objective. The affected cases showed profound impairment in the alpha galactosidase enzyme activity (0.73 ± 1.38% mean normal) while carriers showed 15.64 ± 3.68% mean normal activity. The mutation spectrum is highly heterogeneous with eight different mutations identified in eight different patients in our cohort, while the total data is representative of 68 mutations in Indians. The mean CADD score for these mutations was 20.63 ± 10.38. Highly conserved mutations are associated with renal involvement (

Indexed as

Alpha-galactosidaseEarly onsetFabry diseaseGLAHemizygousWhole exome sequencing

Identifiers

PMID40123633
PMCPMC11928697

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.